CLRB
Cellectar Biosciences, Inc.
Set alert
1.21 USD -0.01 -1.23%
1.18 Day range 1.21
1.12 52-week range 4.04
- YTD
- -59.15%
- 1 year
- -63.04%
- Open
- 1.20
- Prev close
- 1.22
- Mkt cap
- 11.39M
- Vol
- 55.29K
- Avg vol
- 87.96K
- EPS
- -3.46
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.18
- High
- 1.21
- Forward P/E
- -0.10
- Beta
- 1.01
- Short ratio
- 8.34
- Inst. own
- 34.55%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.60
- 200-d avg
- 2.48
- 1y target
- 5.67
Key statistics
- Market cap
- 11.38M
- Enterprise value
- 59.34M
- Trailing P/E
- 0.00
- Forward P/E
- -0.10
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -1.41
- Beta
- 1.01
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -20.48M
- Total cash
- 25.87M
- Total debt
- 530.86K
- Return on equity
- -796.67%
- Shares outstanding
- 41.27M
- Short % of float
- 5.06%
- 50-day average
- 1.60
- 200-day average
- 2.48
Analyst view
Consensus: buy
Buy
Price target (mean) 5.67 +370.3% upside
Now 1.21
- Target (low)
- 1.00
- Target (mean)
- 5.67
- Target (high)
- 13.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.3525.
Financials — quick view
CLRB Revenue — quarterly 0
CLRB Net income — quarterly -6.93M
CLRB EPS — quarterly -0.57
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 18, 2024 | Sep 1, 2024 | -0.35 | -0.55 | -0.20 | -57.14% |
| May 14, 2024 | Mar 1, 2024 | -0.50 | -0.40 | +0.10 | +20.00% |
| Mar 27, 2024 | Dec 1, 2023 | -0.59 | -0.66 | -0.07 | -11.86% |
| Aug 14, 2023 | Jun 1, 2023 | -0.69 | -0.73 | -0.04 | -5.80% |
| May 4, 2023 | Mar 1, 2023 | -0.75 | -0.76 | -0.01 | -1.33% |
| Mar 9, 2023 | Dec 1, 2022 | -0.83 | -0.55 | +0.28 | +33.73% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | Oppenheimer | down | Outperform | Perform |
| Nov 19, 2024 | Oppenheimer | main | Outperform | Outperform |
| Mar 28, 2024 | Roth MKM | main | Buy | Buy |
| Mar 28, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Mar 4, 2024 | Roth MKM | reit | Buy | Buy |
| Nov 4, 2022 | HC Wainwright & Co. | main | — | Buy |
About Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cellectar.com
News
- Cellectar Biosciences Reports Results From Case Study Highlighting Durable Complete Response In Heavily Pretreated Patient With Diffuse Large B-Cell Lymphoma Treated With Iopofosine I 131
- Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
- Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
- Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
- Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript
- Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
- Cellectar Biosciences Q2 2026 Earnings Call Transcript
- Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Your note
Sign in to keep a note on CLRB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARUSO JAMES V | Chief Executive Officer | Stock Award(Grant) | Dec 7, 2023 | 49,236 |
| KOLEAN CHAD J | Chief Financial Officer | Stock Award(Grant) | Dec 7, 2023 | 42,578 |
| LEA DARRELL SHANE | Officer | Stock Award(Grant) | Dec 7, 2023 | 39,599 |
| LONGCOR JARROD | Chief Operating Officer | Stock Award(Grant) | Dec 7, 2023 | 53,141 |
| SHUSTOV ANDREI | Officer | Stock Award(Grant) | Dec 7, 2023 | 55,037 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | 8.90% | 3,671,550 | 1.01M | Sep 29, 2024 |
| AIGH Capital Management LLC | 7.75% | 3,197,394 | 881.52K | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 6.57% | 2,712,443 | 747.82K | Sep 29, 2024 |
| Vanguard Group Inc | 4.18% | 1,726,986 | 476.13K | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 2.48% | 1,022,161 | 281.81K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.85% | 352,452 | 97.17K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.60% | 1,072,704 | 295.74K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.38% | 568,753 | 156.81K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.44% | 179,877 | 49.59K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.20% | 81,910 | 22.58K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 61,939 | 17.08K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 42,426 | 11.70K | Oct 30, 2024 |